ArticleBMC nephrology2021
Cigarette smoking may accelerate the progression of IgA nephropathy.
Article in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Sexually dimorphic response to tobacco in the development of chronic kidney disease: a systematic review.BMC nephrology · 2024Pooled it
- Smoking exposure and long-term progression of IgA nephropathy: a retrospective cohort study of 9,560 patients.Renal failure · 2026Article
- The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.Advances in therapy · 2026Article
- Effects of Flammable and Non-Flammable Nicotine Products on Kidney Health.Medical sciences (Basel, Switzerland) · 2026Review
- Prevalence and Associated Factors of Renal Disease in Saudi Residents Attending Primary Health Care Centers in Riyadh, Saudi Arabia: Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- Iptacopan in Patients With IgA Nephropathy From East Asia.Kidney international reports · 2026Article
- The level and clinical significance of serum soluble M-type phospholipase A2 receptor in patients with primary membranous nephropathy.Renal failure · 2025Article
- Nicotinism vs. Glomerulopathies-Smoking as a Risk Factor for Primary Glomerulopathies.Antioxidants (Basel, Switzerland) · 2025Review
- Risk Stratification in Immunoglobulin A Nephropathy Using Network Biomarkers: Development and Validation Study.Journal of medical Internet research · 2025Article
- Towards Risk Stratification in Clinical Care for IgA Nephropathy: Genetic Risk Scores: Comments on the Study "Clinical Application of Polygenic Risk Score in IgA Nephropathy".Phenomics (Cham, Switzerland) · 2024Article
- Cigarette smoking and progression of kidney dysfunction: a longitudinal cohort study.Clinical and experimental nephrology · 2024Article
- High mobility group box 1 (HMGB1) mediates nicotine-induced podocyte injury.Frontiers in pharmacology · 2024Article
- The hidden impact: the rate of nicotine metabolism and kidney health.Frontiers in endocrinology · 2024Article
- IgA nephropathy.Nature reviews. Disease primers · 2023Review
- The Association of Smoking and Hyperuricemia with Renal Arteriolosclerosis in IgA Nephropathy.Biomedicines · 2023Article
- New insights into pathogenesis of IgA nephropathy.International urology and nephrology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether cigarette smoking is associated with the progression of immunoglobulin A nephropathy (IgAN) remains uncertain; therefore, we aimed to evaluate the effect of cigarette smoking on the prognosis of IgAN.
methodsWe divided 1239 IgAN patients from West China Hospital of Sichuan University who met the inclusion criteria into smoker (current or former) and non-smoker groups. The endpoint was end-stage renal disease (ESRD: eGFR < 15 mL/min/1.73 m
resultsDuring the mean follow-up period of 61 months, 19% (40/209) of the smoker group and 11% (110/1030) of the non-smoker group reached the study endpoint (p < 0.001). Multivariate Cox regression analysis revealed that cigarette smoking (hazard ratio (HR) = 1.58; p = 0.043) was an independent risk factor predicting poor renal progression in IgAN, and that IgAN patients with chronic kidney disease (CKD) stage 3-4 were more susceptible to cigarette smoking (p < 0.001). After propensity score matching (PSM), a significant correlation between cigarette smoking and renal outcomes in IgAN patients was seen. Furthermore, Spearman's correlation test revealed that smoking dose was negatively correlated with eGFR (r = 0.141; p < 0.001) and positively related with proteinuria (r = 0.096; p = 0.001).
conclusionsCigarette smoking is an independent risk factor for IgAN progression, especially for advanced patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.